Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer

Umene,Kiyoko; Yanokura,Megumi; Banno,Kouji; Irie,Haruko; Adachi,Masataka; Iida,Miho; Nakamura,Kanako; Nogami,Yuya; Masuda,Kenta; Kobayashi,Yusuke; Tominaga,Eiichiro; Aoki,Daisuke

doi:10.3892/ijo.2015.2842

Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer

Authors:
- Kiyoko Umene
- Megumi Yanokura
- Kouji Banno
- Haruko Irie
- Masataka Adachi
- Miho Iida
- Kanako Nakamura
- Yuya Nogami
- Kenta Masuda
- Yusuke Kobayashi
- Eiichiro Tominaga
- Daisuke Aoki
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
Published online on: January 22, 2015 https://doi.org/10.3892/ijo.2015.2842
Pages: 1498-1506
Copyright: © Umene et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aurora kinase A (AURKA) regulates the cell cycle checkpoint and maintains genomic integrity. AURKA is overexpressed in various malignant tumors and its upregulation induces chromosomal instability, which leads to aneuploidy and cell transformation. To investigate the role of AURKA in endometrial cancer, we evaluated the association of immunohistochemical expression of AURKA with clinicopathological factors. Furthermore, we examined the effects of AURKA inhibition by transfected siRNA in HEC‑1B cells on colony‑forming ability, invasion and migration capacity, and chemosensitivity. Immunohistochemical staining showed that overexpression of AURKA was significantly associated with tumor grade (P<0.05) and poor histologic differentiation (P<0.05). The recurrence rate also tended to be high in cases with overexpression of AURKA (P<0.1) and these cases also had a tendency for shorter disease‑free survival (DFS) (P<0.1). AURKA inhibition in endometrial cancer cell lines significantly decreased cell growth, invasion and migration (P<0.05), and increased chemosensitivity to paclitaxel. We also evaluated the efficacy of a combination of AURKA siRNA and paclitaxel against subcutaneous tumors formed in a nude mouse. After treatment, the tumor volume shrank significantly compared to treatment with paclitaxel only (P<0.05). To our knowledge, this is the first study in endometrial carcinoma to show a correlation between overexpression of AURKA and tumor grade, histological type and sensitivity to paclitaxel. AURKA is a promising therapeutic target in endometrial cancer and the combination therapy with AURKA inhibitors and paclitaxel could be effective for endometrial cancer that is resistant to conventional treatment and has a poor prognosis.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008 v20, Cancer Incidence and Mortality Worldwide. International Agency for Research on Cancer; Lyon: 2010, http://globocan.iarc.fr.
2	Murali R, Soslow RA and Weigelt B: Classification of endometrial carcinoma: more than two types. Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
4	Marumoto T, Zhang D and Saya H: Aurora-A - a guardian of poles. Nat Rev Cancer. 5:42–50. 2005. View Article : Google Scholar : PubMed/NCBI
5	Glover DM, Leibowitz MH, McLean DA and Parry H: Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 81:95–105. 1995. View Article : Google Scholar : PubMed/NCBI
6	Zhou H, Kuang J, Zhong L, et al: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 20:189–193. 1998. View Article : Google Scholar : PubMed/NCBI
7	Katayama H, Brinkley WR and Sen S: The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22:451–464. 2003. View Article : Google Scholar : PubMed/NCBI
8	Katayama H, Sasai K, Kawai H, et al: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 36:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
9	Cazales M, Schmitt E, Montembault E, Dozier C, Prigent C and Ducommun B: CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle. 4:1233–1238. 2005. View Article : Google Scholar : PubMed/NCBI
10	Nishida N, Nagasaka T, Kashiwagi K, Boland CR and Goel A: High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther. 6:525–533. 2007. View Article : Google Scholar : PubMed/NCBI
11	Sen S, Zhou H, Zhang RD, et al: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst. 94:1320–1329. 2002. View Article : Google Scholar : PubMed/NCBI
12	Li D, Zhu J, Firozi PF, et al: Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 9:991–997. 2003.PubMed/NCBI
13	Sakakura C, Hagiwara A, Yasuoka R, et al: Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer. 84:824–831. 2001. View Article : Google Scholar : PubMed/NCBI
14	Sen S, Zhou H and White RA: A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene. 14:2195–2200. 1997. View Article : Google Scholar : PubMed/NCBI
15	Landen CN Jr, Lin YG, Immaneni A, et al: Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res. 13:4098–4104. 2007. View Article : Google Scholar : PubMed/NCBI
16	Lassmann S, Shen Y, Jütting U, et al: Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res. 13:4083–4091. 2007. View Article : Google Scholar : PubMed/NCBI
17	Umene K, Banno K, Kisu I, et al: Aurora kinase inhibitors: potential molecular-targeted drugs for gynecologic malignant tumors. Biomed Rep. 1:335–340. 2013.
18	Do TV, Xiao F, Bickel LE, et al: Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 33:539–549. 2014. View Article : Google Scholar
19	Kurai M, Shiozawa T, Shih HC, et al: Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol. 36:1281–1288. 2005. View Article : Google Scholar : PubMed/NCBI
20	Moreno-Bueno G, Sánchez-Estévez C, Cassia R, et al: Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 63:5697–5702. 2003.PubMed/NCBI
21	Tanaka E, Hashimoto Y, Ito T, et al: The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res. 11:1827–1834. 2005. View Article : Google Scholar : PubMed/NCBI
22	Anand S, Penrhyn-Lowe S and Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 3:51–62. 2003. View Article : Google Scholar : PubMed/NCBI
23	Tanaka E, Hashimoto Y, Ito T, et al: The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res. 13:1331–1340. 2007. View Article : Google Scholar : PubMed/NCBI
24	Li Y, Tang K, Zhang H, Zhang Y, Zhou W and Chen X: Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp. Mol Med Rep. 4:739–746. 2011.PubMed/NCBI
25	Cammareri P, Scopelliti A, Todaro M, et al: Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 70:4655–4665. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hata T, Furukawa T, Sunamura M, et al: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 65:2899–2905. 2005. View Article : Google Scholar : PubMed/NCBI
27	Yang F, Guo X, Yang G, Rosen DG and Liu J: AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Mod Pathol. 24:836–845. 2011. View Article : Google Scholar : PubMed/NCBI
28	Du J and Hannon GJ: Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion. Proc Natl Acad Sci USA. 101:8975–8980. 2004. View Article : Google Scholar : PubMed/NCBI
29	Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A and Horii A: AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 25:4831–4839. 2006. View Article : Google Scholar : PubMed/NCBI
30	Yang G, Chang B, Yang F, et al: Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 16:3171–3181. 2010. View Article : Google Scholar : PubMed/NCBI
31	Goos JA, Coupe VM, Diosdado B, et al: Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer. 109:2445–2452. 2013. View Article : Google Scholar : PubMed/NCBI
32	Yamamoto S, Yamamoto-Ibusuki M, Yamamoto Y, Fujiwara S and Iwase H: A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer. BMC Cancer. 13:2172013. View Article : Google Scholar : PubMed/NCBI
33	Yen CC, Yeh CN, Cheng CT, et al: Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of Aurora kinase A as a poor risk marker. Ann Surg Oncol. 19:3491–3499. 2012. View Article : Google Scholar : PubMed/NCBI
34	Royce ME, Xia W, Sahin AA, et al: STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer. 100:12–19. 2004. View Article : Google Scholar
35	Hamada M, Yakushijin Y, Ohtsuka M, Kakimoto M, Yasukawa M and Fujita S: Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin’s lymphoma. Br J Haematol. 121:439–447. 2003. View Article : Google Scholar : PubMed/NCBI
36	Chen SS, Chang PC, Cheng YW, Tang FM and Lin YS: Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J. 21:4491–4499. 2002. View Article : Google Scholar : PubMed/NCBI
37	Liu Q, Kaneko S, Yang L, et al: Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 279:52175–52182. 2004. View Article : Google Scholar : PubMed/NCBI
38	Tatsuka M, Sato S, Kitajima S, et al: Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene. 24:1122–1127. 2005. View Article : Google Scholar
39	Guan Z, Wang XR, Zhu XF, et al: Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res. 67:10436–10444. 2007. View Article : Google Scholar : PubMed/NCBI
40	Yang H, He L, Kruk P, Nicosia SV and Cheng JQ: Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 119:2304–2312. 2006. View Article : Google Scholar : PubMed/NCBI
41	Wan XB, Long ZJ, Yan M, et al: Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis. 29:1930–1937. 2008. View Article : Google Scholar : PubMed/NCBI
42	Jeng YM, Peng SY, Lin CY and Hsu HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 10:2065–2071. 2004. View Article : Google Scholar : PubMed/NCBI
43	Lin Y, Richards FM, Krippendorff BF, et al: Paclitaxel and CYC3, an Aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. Br J Cancer. 107:1692–1701. 2012. View Article : Google Scholar : PubMed/NCBI
44	Long M, Yin G, Liu L, et al: Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells. Cancer Gene Ther. 19:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
45	Lee HH, Zhu Y, Govindasamy KM and Gopalan G: Down-regulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. Endocr Relat Cancer. 15:765–775. 2008. View Article : Google Scholar : PubMed/NCBI
46	Agnese V, Bazan V, Fiorentino FP, et al: The role of Aurora-A inhibitors in cancer therapy. Ann Oncol. 18(Suppl 6): vi47–vi52. 2007. View Article : Google Scholar : PubMed/NCBI
47	Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr and Gandara DR: Aurora kinases as anticancer drug targets. Clin Cancer Res. 14:1639–1648. 2008. View Article : Google Scholar : PubMed/NCBI